U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07375758) titled 'A Phase I/II Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.' on Jan. 22.
Brief Summary: This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Immunoglobulin A Nephropathy
Intervention:
DRUG: MIL116
MIL116 is supplied as sterile solution for subcutaneous (SC) injection.
DRUG: Matching Placebo
Placebo is to be administered at a matching volume by SC injection.
Recruitment Status: NOT_YE...